What you need to know about a new anti-malaria drug

The anti-infective drug used to treat malaria and other infections could help save millions of lives by preventing more of the deadly viruses that infect us, according to the world’s leading malaria experts.

In a series of research articles published Tuesday in The Lancet Infectious Diseases, the researchers from the University of Nottingham and Johns Hopkins University in Baltimore described a drug developed to treat the disease that can block its viral replication.

The drug is called Pravicin, and it has been developed in collaboration with Oxford University in the United Kingdom, the scientists wrote.

Pravacin, which is already approved in the U.K., has a half-life of more than a year.

It has a molecular weight of 3,000, and a half of that weight comes from the Pravc1 gene, which encodes the Parnak protein, the enzyme that converts the Prenatice virus genome into its more common and deadly forms.

Pravic, the team reported, also inhibits the virus from infecting other cells in the body, such as the lung and the pancreas.

The drug can also reduce the virus’s ability to infect cells in blood vessels, the kidneys and other organs.

Its use has been on the rise in recent years as the disease has become increasingly resistant to existing treatments.

In 2016, a drug approved by the FDA, Pravixin, had a half life of two weeks, and Pravaxone, another approved drug, had only a three-week half-lives.

But these drugs can have only so many doses, and are usually given only once a day.

Parnak is the main cause of malaria, the most common parasitic infection in the world, and kills about 40 million people a year worldwide.

The virus also causes hundreds of thousands of deaths each year in children.

Povacin was developed in partnership with the Oxford team and their partner in the Pernatal Immunobiology Laboratory at Oxford University, which was established in 1851 to study the causes and treatment of the disease.

The Parnacin group is led by Dr. James O’Brien, a senior scientist at the University’s Department of Immunology.

O’Brien is also a member of the Oxford group.

His group is also developing a drug to treat patients with the more serious form of the virus called Zaire dengue, which affects about 10 million people worldwide.

That drug, Povirax, was approved by Pfizer in September, 2016, and is in the final stages of being licensed by the U